NCT02478164View on ClinicalTrials.gov

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 13, 2015

Primary Completion Date

July 8, 2017

Study Completion Date

May 9, 2018

Conditions
Glioblastoma
Interventions
DRUG

Ponatinib

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02478164 - Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | Biotech Hunter | Biotech Hunter